Lakefront Biotherapeutics (LKFT) reported $1.3B in revenue for fiscal 2025, +321.2% year on year. That ranks #1631 by revenue among 2853 SEC filers and #151 in Healthcare. Net income was $363M, a net margin of 28.9%. Revenue has grown 39.9% a year on average since 2015 ($43.9M then). The fiscal 2025 balance sheet shows $4.0B in total assets and $103M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| Revenue€1.1B | $1.3B | +321.2% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating income€295M | $333M | +$537M | FY20252025-12-31 |
| Net income€321M | $363M | +352.2% | FY20252025-12-31 |
| Operating cash flow−€257M | −$291M | +$55.5M | FY20252025-12-31 |
| Capital expenditure€13.7M | $15.5M | −14.4% | FY20252025-12-31 |
| Total assets€3.4B | $4.0B | −6.8% | FY20252025-12-31 |
| Shareholders' equity€3.2B | $3.8B | +26.3% | FY20252025-12-31 |
| Cash€87.9M | $103M | +54.7% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 12 of 161 companies compared | 28.9% | |
| Operating marginRank 20 of 160 companies compared | 26.5% | |
| R&D as share of revenueRank 5 of 102 companies compared | 41.3% | |
| Cash as share of revenueRank 103 of 160 companies compared | 8.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Lakefront Biotherapeutics NV
- Ticker
- LKFT
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- CIK
- 0001421876
Filings
- 20-FMar 26, 2026Open filing →
- 20-FMar 27, 2025Open filing →
- 20-FMar 28, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Phibro Animal HealthPAHC | $1.3B | $48.3M |
| ProgynyPGNY | $1.3B | $58.5M |
| Curaleaf HoldingsCURLF | $1.3B | −$231M |
| Lakefront BiotherapeuticsLKFT | $1.3B | $363M |
| Indivior PharmaceuticalsINDV | $1.2B | $210M |
| Nasus PharmaNSRX | $1.2B | −$5.9M |
| Bio-TechneTECH | $1.2B | $73.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Lakefront Biotherapeutics — Key figures |url=https://companiesranked.com/en/company/lakefront-biotherapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Lakefront Biotherapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/lakefront-biotherapeuticsBibTeX
@misc{companiesranked-en-company-lakefront-biotherapeutics-2026,
author = {{CompaniesRanked}},
title = {{Lakefront Biotherapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/lakefront-biotherapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001104659-26-035163 · March 26, 2026
{{cite web |title=Lakefront Biotherapeutics — Key figures — 20-F (0001104659-26-035163) |url=https://www.sec.gov/Archives/edgar/data/1421876/000110465926035163/glpg-20251231x20f.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.